Abstract：Head and neck osteosarcoma is a rare tumor. Its clinical features and recurrence pattern are different from those of osteosarcoma in other parts. Osteosarcoma of the head and neck occurs late with a high local recurrence rate and a low distant metastasis rate. Local recurrence is the main cause of death. Surgery is the main treatment. Postoperative radiotherapy is recommended for patients with positive surgical margin,proximal incisional margin and uncertain surgical margin. The role of chemotherapy remains controversial. Effective molecular targeted therapeutics need to be further explored for recurrent, metastatic and unresectable osteosarcoma,.
Liu Zhiping,Zhang Daxin,Pan Jie et al. Current status of treatment for osteosarcoma of head and neck[J]. Chinese Journal of Radiation Oncology, 2019, 28(10): 780-783.
[1] Lagmay JP,Krailo MD,Dang H,et al. Outcome of patients with recurrent osteosarcoma enrolled in seven phase Ⅱ trials through children′s cancer group,pediatric oncology group,and children′s oncology group:learning from the past to move forward[J]. J Clin Oncol,2016,34:3031-3038. DOI:10.1200/JCO.2015.65.5381. [2] Thariat J,Julieron M,Brouchet A,et al. Osteosarcomas of the mandible:Are they different from other tumor sites?[J]. Crit Rev Oncol Hematol,2012,82(3):280-295. DOI:10.1016/j.critrevonc.2011.07.001. [3] Kmmerer PW,Shabazfar N,Makoie NV,et al. Clinical,therapeutic and prognostic features of osteosarcoma of the jaws-Experience of 36 cases[J]. J Craniomaxillofac Surg,2012,40(6):541-548. DOI:10.1016/j.jcms.2011.10.001. [4] Granowski-LeCornu M,Chuang SK,Kaban LB,et al. Osteosarcoma of the jaws:factors influencing prognosis[J]. J Oral Maxillofac Surg,2011,69(9):2368-2375. DOI:10.1016/j.joms.2010.10.023. [5] van den Berg H,Merks JH. Incidence and grading of cranio-facial osteosarcomas[J]. Int J Oral Maxillofac Surg,2014,43(1):7-12. DOI:10.1016/j.ijom.2013.06.017. [6] Patel SG,Meyers P,Huvos AG,et al. Improved outcomes in patients with osteogenic sarcoma of the head and neck[J]. Cancer,2002,95(7):1495-1503. DOI:10.1002/cncr.10849. [7] Kassir RR,Rassekh CH,Kinsella JB,et al. Osteosarcoma of the head and neck:meta-analysis of nonrandomized studies[J]. Laryngoscope,1997,107(1):56-61. DOI:10.1097/00005537-199701000-00013. [8] Huber GF,Dziegielewski P,Wayne Matthews T,et al. Head and neck osteosarcoma in adults:the province of Alberta experience over 26 years[J]. J Otolaryngol Head Neck Surg,2008,37(5):738-743. DOI:10.1097/scs.0b013e3181869df1. [9] Boon E,van der Graaf WT,Gelderblom H,et al.Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults[J]. Head Neck,2017,39(1):140-146. DOI:10.1002/hed.24556. [10] van Es RJ,Keus RB,van der Waal I,et al. Osteosarcoma of the jaw bones. Long-term follow up of 48 cases[J]. Int J Oral Maxillofac Surg,1997,26(3):191-197. DOI:10.1016/S0901-5027(97)80818-1. [11] Harrison DJ,Geller DS,Gill JD,et al. Current and future therapeutic approaches for osteosarcoma[J]. Expert Rev Anticancer Ther,2018,18(1):39-50. DOI:10.1080/14737140.2018.1413939. [12] Liang L,Zhang T,You Y,et al. An individual patient data meta-analysis on the effect of chemotherapy on survival in patients with craniofacial osteosarcoma[J]. Head Neck,2019,1. DOI:10.1002/hed.25668. [13] Smeele LE,Kostense PJ,van der Waal I,et al. Effect of chemotherapy on survival of craniofacial osteosarcoma:a systematic review of 201 patients[J]. J Clin Oncol,1997,15(1):363-367. DOI:10.1200/JCO.1997.15.1.363. [14] Smith RB,Apostolakis LW,Karnell LH,et al. National cancer data base report on osteosarcoma of the head and neck[J]. Cancer,2003,98(8):1670-1680. DOI:10.1002/cncr.11716. [15] 黄兰柱,唐恩溢,丁洁,等. 颌面部肉瘤临床疗效分析[J]. 口腔医学研究,2012,28:714-716. DOI:10.13701/j.cnki.kqyxyj.2012.07.009. Huang LZ,Tang EY,Ding J,et al. Clinical analysis of maxillofacial sarcoma[J]. J Oral Scien Res,2012,28:714-716. DOI:10.13701/j.cnki.kqyxyj.2012.07.009. [16] DeAngelis AF,Spinou C,Tsui A,et al. Outcomes of patients with maxillofacial osteosarcoma:a review of 15 cases[J]. J Oral Maxillofac Surg,2012,70(3):734-739. DOI:10.1016/j.joms.2011.03.020. [17] Jasnau S,Meyer U,Potratz J,et al. Craniofacial osteosarcoma experience of the cooperative German–Austrian–Swiss osteosarcoma study group[J]. Oral Oncol,2008,44(3):286-294. DOI:10.1016/j.oraloncology.2007.03.001. [18] Guadagnolo BA,Zagars GK,Raymond AK,et al. Osteosarcoma of the jaw/craniofacial region:outcomes after multimodality treatment[J]. Cancer,2009,115(14):3262-3270. DOI:10.1002/cncr.24297. [19] Laskar S,Basu A,Muckaden MA,et al. Osteosarcoma of the head and neck region:lessons learned from a single-institution experience of 50 patients[J]. Head Neck,2008,30(8):1020-1026. DOI:10.1002/hed.20820. [20] Bielack S,Jürgens H,Jundt G,et al. Osteosarcoma:The COSS Experience[J]. Cancer Treat Res,2009,152(2):289-308. DOI:10.1007/978-1-4419-0284-9_15. [21] DeLaney TF,Park L,Goldberg SI,et al. Radiotherapy for local control of osteosarcoma[J]. Int J Radiat Oncol Biol Phys,2005,61(2):492-498. DOI:10.1016/j.ijrobp.2004.05.051. [22] Machak GN,Tkachev SI,Solovyev YN,et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities[J]. Mayo Clin Proc,2003,78(1):147-155. [23] Caceres E,Zaharia M,Valdivia S,et al. Local control of osteogenic sarcoma by radiation and chemotherapy[J]. Int J Radiat Oncol Biol Phys,1984,10(1):35-39. [24] Bielack SS,Hecker-Nolting S,Blattmann C,et al. Advances in the management of osteosarcoma[J]. Ver Res,2016,5:2767. DOI:10.12688/f1000research.9465.1. [25] Ciernik IF,Niemierko A,Harmon DC,et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma[J]. Cancer,2011,117(19):4522-4530. DOI:10.1002/cncr.26037. [26] Matsunobu A,Imai R,Kamada T,et al.:Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk[J]. Cancer,2012,118(18):4555-4563. DOI:10.1002/cncr.27451. [27] Ketabchi A,Kalavrezos N,Newman L. Sarcomas of the head and neck:a 10-year retrospective of 25 patients to evaluate treatment modalities,function and survival[J]. Br J Oral Maxillofac Surg,2011,49(2):116-120. DOI:10.1016/j.bjoms.2010.02.012. [28] Chen Y,Shen Q,Gokavarapu S,Lin C,et al. Osteosarcoma of head and neck:a retrospective study on prognostic factors from a single institute database[J]. Oral Oncol,2016,58(1):1-7. DOI:10.1016/j.oraloncology.2016.04.008. [29] Oda D,Bavisotto LM,Schmidt RA,et al. Head and neck osteosarcoma at the university of Washington[J]. Head Neck,1997,19(6):513-523. DOI:10.1002/(SICI)1097-034(199709)19:6<513. [30] Thariat J,Schouman T,Brouchet A,et al. Osteosarcomas of the mandible:multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO,Rare Cancer Network,GETTEC/REFCOR and SFCE[J]. Ann Oncol,2013,24(3):824-831. DOI:10.1093/annonc/mds507. [31] Anninga JK,Gelderblom H,Fiocco M,et al. Chemotherapeutic adjuvant treatment for osteosarcoma:where do we stand[J]?. Eur J Cancer,2011,47(16):2431-2445. DOI:10.1016/j.ejca.2011.05.030. [32] Thiele OC,Freier K,Bacon C,et al. Inter-disciplinary combined treatment of craniofacial osteosarcoma with neoadjuvant and adjuvant chemotherapy and excision of the tumour:a retrospective study[J]. Br J Oral Maxillofac Surg,2008,46(7):533-536. DOI:10.1016/j.bjoms.2008.03.010. [33] Mardinger O,Givol N,Talmi YP,et al. Osteosarcoma of thejaw.The Chaim Sheba Medical Center experience[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2001,91(4):445-451. DOI:10.1067/moe.2001.112330. [34] Grignani G,Palmerini E,Dileo P,et al. A phase Ⅱ trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy:an Italian Sarcoma Group study[J]. Ann Oncol,2012,23(2):508-516. DOI:10.1093/annonc/mdr151. [35] Grignani G,Palmerini E,Ferraresi V,et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment:a non-randomised phase 2 clinical trial[J]. Lancet Oncol,2015,16(1):98-107. DOI:10.1016/S1470-2045(14)71136-2. [36] Ebb D,Meyers P,Grier H,et al. Phase Ⅱ trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression:A report from the Children′s Oncology Group[J]. J Clin Oncol,2012,30(20):2545-2551. DOI:10.1200/JCO.2011.37.4546. [37] Xie L,Ji T,Guo W. Anti-angiogenesis target therapy for advanced osteosarcoma (Review)[J]. Oncol Rep,2017,38(2):625-636. DOI:10.3892/or.2017.5735. [38] Tawbi HA,Burgess M,Bolejack V,et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARCO28):a multicentre,two-cohort,single-arm,open-label,phase 2 trial[J]. Lancet Oncol,2017,18(11):1493-1501. DOI:10.1016/S1470-2045(17)30624-1. [39] Paoluzzi L,Cacavio A,Ghesani M,et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas[J]. Clin Sarcoma Res,2016,6(1):24. DOI:10.1186/s13569-016-0064-0.
2019, Vol. 28 
